Development of a Test Cancer BioChip for the Cancer BioChip System

开发用于癌症生物芯片系统的测试癌症生物芯片

• 批准号: 8003470
• 负责人: RULA A ABBUD-ANTAKI
• 金额: $ 26.96万
• 依托单位: FALCON GENOMICS, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8003470
• 关键词: Agar; Anchorage-Independent Growth; Antineoplastic Agents; Applications Grants; Biological Assay; Breast Cancer Cell; Cancer Cell Growth; Cancer Diagnostics; Cancer Etiology; Cancer Patient; Cells; Chemosensitivity Assay; Clinical Trials; Computer software; Custom; Cytostatics; DNA Microarray Chip; Development; Devices; Diagnosis; Diagnostic tests; Disease Progression; Effectiveness; Equipment; Evaluation; Future; Gene Expression; Gene Targeting; Generations; Genes; Genomics; Gold; Growth; Human; Image; Image Analysis; Label; Life; Malignant Neoplasms; Marketing; Mediating; Microarray Analysis; Microscopic; Mission; Molecular Profiling; Monitor; Oncogenes; One-Step dentin bonding system; Outcome; Patient Selection; Patients; Performance; Pharmaceutical Preparations; Phase; Phase III Clinical Trials; RNA; RNA Interference; Reagent; Recommendation; Recurrence; Robot; Role; Sampling; Screening procedure; Services; Solutions; System; Testing; Therapeutic; Transfection; Translating; Tumor Stem Cell Assay; United States National Institutes of Health; Validation; Variant; base; biochip; cancer cell; cancer therapy; cancer type; cellular imaging; cost; density; design; genetic profiling; high throughput screening; in vivo; inhibitor/antagonist; malignant breast neoplasm; meetings; metaplastic cell transformation; miniaturize; neoplastic cell; novel; public health relevance; research clinical testing; small hairpin RNA; technological innovation; therapeutic target; tool; tumor; tumor growth

DESCRIPTION (provided by applicant): Recent genomic breakthroughs have revolutionized our understanding of cancer. It is now possible to envision treatment paradigms that would be individualized, targeted and tailored according to the tumor genetic profile. However, high-throughput functional assays capable of identifying and validating potential cancer drugs, based on abnormal tumor gene expression profiles, in a setting that would directly translate to providing recommendations for patient treatment are not readily available. The human tumor stem cell assay (HTSCA), also known as anchorage-independent growth assay, has been considered as the "gold standard" for chemosensitivity testing of patient tumor cells. In its current format, the HTSCA suffers from many pitfalls that make it unfit for high-throughput clinical testing. Falcon Genomics, Inc. is developing the Cancer BioChip System (CBCS), a rapid, high-throughput, automated, and quantitative anchorage-independent growth assay for the personalized identification and validation of inhibitors of cancer cell growth. We will use silencing RNA (siRNA) or short hairpin RNA (shRNA) to inhibit expression of abnormally expressed tumor genes and test their impact on anchorage-independent tumor growth in a high-throughput fashion. In this Phase I application, we will develop a Test Cancer BioChip for optimizing plating, transfection, silencing, and cytostatic efficiencies. Results from these studies will validate the CBCS as a tool for cancer target identification and validation. Through future clinical trials, we anticipate development of the CBCS into a cancer diagnostic and personalized therapeutic tool. PUBLIC HEALTH RELEVANCE: This Phase-1 grant application is relevant to the mission of the National Institute of Health since it will provide for a Cancer BioChip System that will assist in the diagnosis and development of cancer therapies. It will initially offer a novel personalized approach to the evaluation and treatment of breast cancer patients. However, it is not limited to breast cancer since all types of cancers that are capable of growing in an anchorage-independent fashion can be tested on the Cancer BioChip System.

描述（由申请人提供）：最近的基因组突破彻底改变了我们对癌症的理解。现在可以设想根据肿瘤遗传谱进行个体化、有针对性和定制的治疗范例。然而，能够根据异常肿瘤基因表达谱识别和验证潜在癌症药物的高通量功能测定，在直接转化为为患者治疗提供建议的环境中，目前尚不可用。人类肿瘤干细胞测定（HTSCA），也称为贴壁独立生长测定，被认为是患者肿瘤细胞化学敏感性测试的“金标准”。在目前的格式下，HTSCA 存在许多缺陷，使其不适合高通量临床测试。 Falcon Genomics, Inc. 正在开发癌症生物芯片系统 (CBCS)，这是一种快速、高通量、自动化、定量的不依赖锚定的生长测定方法，用于个性化鉴定和验证癌细胞生长抑制剂。我们将使用沉默 RNA (siRNA) 或短发夹 RNA (shRNA) 来抑制异常表达的肿瘤基因的表达，并以高通量方式测试它们对锚定非依赖性肿瘤生长的影响。在此一期应用中，我们将开发一种测试癌症生物芯片，用于优化铺板、转染、沉默和细胞抑制效率。这些研究的结果将验证 CBCS 作为癌症靶标识别和验证的工具。通过未来的临床试验，我们预计 CBCS 将发展成为癌症诊断和个性化治疗工具。 公共健康相关性：这一第一阶段拨款申请与美国国立卫生研究院的使命相关，因为它将提供癌症生物芯片系统，协助癌症疗法的诊断和开发。它最初将提供一种新颖的个性化方法来评估和治疗乳腺癌患者。然而，它不仅限于乳腺癌，因为能够以不依赖锚定的方式生长的所有类型的癌症都可以在癌症生物芯片系统上进行测试。

项目成果

Validation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targets.

• DOI: 10.1371/journal.pone.0046086
• 发表时间: 2012
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Marhefka JN;Abbud-Antaki RA
• 通讯作者: Abbud-Antaki RA

The Cancer BioChip System: a functional genomic assay for anchorage-independent three-dimensional breast cancer cell growth.

癌症生物芯片系统：用于不依赖锚定的三维乳腺癌细胞生长的功能基因组测定。

• DOI: 10.1007/s12672-012-0116-8
• 发表时间: 2012
• 期刊: Hormones & cancer
• 影响因子: 3
• 作者: Abbud-Antaki,RulaA;Marhefka,JoieN;DeLuca,AimeeL;Zuromskis,MichaelP
• 通讯作者: Zuromskis,MichaelP